Drug interactions
Obinutuzumab + Ublituximab
Severity: Major
Obinutuzumab and Ublituximab: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both are anti-CD20 antibodies that deplete B cells. Combining them offers no therapeutic advantage and would increase the risk of serious infections, hypogammaglobulinemia and infusion reactions. Hepatitis B reactivation is a class concern.
What this interaction means in plain words
Obinutuzumab and Ublituximab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Obinutuzumab belongs to Oncology; Ublituximab belongs to Miscellaneous.
Why it happens
Duplicate anti-CD20 B-cell depletion producing additive immunosuppression.
What to do
Do not use two anti-CD20 antibodies together. If switching, allow for prolonged B-cell depletion and monitor for infection and immunoglobulin levels.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Obinutuzumab and Ublituximab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Obinutuzumab
Other interactions of Ublituximab
Frequently asked questions
Can I take Obinutuzumab with Ublituximab?
MediHelp rates the interaction as major. Obinutuzumab and Ublituximab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both are anti-CD20 antibodies that deplete B cells. Combining them offers no therapeutic advantage and would increase the risk of serious infections, hypogammaglobulinemia and infusion reactions. Hepatitis B reactivation is a class concern.
How serious is the interaction between Obinutuzumab and Ublituximab?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Do not use two anti-CD20 antibodies together. If switching, allow for prolonged B-cell depletion and monitor for infection and immunoglobulin levels.
What other medicines interact with Obinutuzumab?
MediHelp also lists interactions of Obinutuzumab with, for example, Measles mumps and rubella vaccine, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel. The full list is on the Obinutuzumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
